Revance Therapeutics (RVNC) Misses Q3 EPS by 10c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.37), $0.10 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $59.88 million versus the consensus estimate of $68.18 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Benchmark Starts Boyd Gaming (BYD) at Buy
• Nokia and Google Cloud to integrate Gemini AI into network software
• Hyperion DeFi partners with Blockdaemon for Hyperliquid staking